Vertex Pharmaceuticals recently obtained approval for its non-opioid pain medication. The drug could become a blockbuster and a key part of Vertex's portfolio. The stock has been rising in value ...

Vertex Pharmaceuticals (NASDAQ ... the company can now add to its list of approved drugs. On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with ...

Vertex Pharmaceuticals(NASDAQ ... Learn More » On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment for moderate to severe acute pain.

Vertex Pharmaceuticals (NASDAQ: VRTX ... Learn More » On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment for moderate to severe acute pain. For ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...